Dimensional Fund Advisors LP Sells 76,850 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Dimensional Fund Advisors LP lessened its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 36.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,965 shares of the company's stock after selling 76,850 shares during the period. Dimensional Fund Advisors LP owned about 0.29% of 4D Molecular Therapeutics worth $735,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock worth $4,568,000 after purchasing an additional 504,086 shares in the last quarter. Norges Bank bought a new stake in 4D Molecular Therapeutics during the fourth quarter worth $2,790,000. Peapod Lane Capital LLC acquired a new stake in 4D Molecular Therapeutics in the fourth quarter valued at $806,000. Raymond James Financial Inc. bought a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at about $629,000. Finally, Vanguard Group Inc. lifted its stake in 4D Molecular Therapeutics by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock valued at $15,933,000 after purchasing an additional 92,791 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on FDMT. HC Wainwright restated a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Barclays dropped their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Chardan Capital reduced their price objective on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Bank of America decreased their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Finally, Royal Bank of Canada cut their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Stock Up 10.5%

Shares of FDMT traded up $0.36 during midday trading on Monday, reaching $3.80. 619,194 shares of the stock were exchanged, compared to its average volume of 835,995. The stock's 50 day simple moving average is $3.30 and its 200 day simple moving average is $5.08. The company has a market cap of $176.04 million, a P/E ratio of -1.33 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a twelve month low of $2.24 and a twelve month high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). As a group, analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.